DONATE
GET INVOLVED
Clinical Trial Finder
Other Enrolling
Study of SPI-1005 in people with CF ages 18 and older (Sound Pharma SPI-3005-501.2)
This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.
This study will be randomized and placebo-controlled. This means that some participants will receive SPI-1005 and some will receive a placebo. Participants who receive SPI-1005 will receive one of three dose levels. Researchers will measure safety and tolerability by monitoring for adverse events. They will also track how the body processes SPI-1005 by measuring symptoms of hearing loss and how much of the drug is in the blood.
This study may require hearing tests, lung function tests, blood draws, and/or other measurements.
Study Design
-
Study Type: ?more info
Interventional -
Randomized Study: ?more info
Yes -
Placebo Controlled: ?more info
Yes -
Length of Participation:
49 days -
Number of Study Visits:
6
Additional Information
-
Phase: ?more info
Phase Two -
Study Sponsor: ?more info
Sound Pharma -
Study Drugs:
Study Sites
-
Enrolling
California
University of California San Diego, La Jolla, CA 92093
Contact
Jenna Mielke
Phone: +1 (619) 471-0822
Email: jmielke@ucsd.edu
-
Enrolling Soon
District of Columbia
Children's National Medical Center, Washington, DC 20010
Contact
Beth Harkness
Phone: +1 (202) 476-2215
Email: bharknes@childrensnational.org
-
Enrolling
Florida
University of Miami, Miami, FL 33136
Contact
Patricia Graham
Phone: +1 (305) 243-5545
Email: pgraham1@med.miami.edu
-
Enrolling
Idaho
Saint Luke's Cystic Fibrosis Center of Idaho, Boise, ID 83702
Contact
Lejla Godusevic
Phone: +1 (208) 381-4717
Email: godusevl@slhs.org
-
Enrolling Soon
Indiana
Indiana University Medical Center, Indianapolis, IN 46202
Contact
Lisa Bendy
Phone: +1 (317) 278-7152
Email: lbendy@iupui.edu
-
Enrolling
Kansas
University of Kansas Medical Center, Kansas City, KS 66160
Contact
Lawrence Scott
Phone: +1 (913) 588-4020
Email: lscott2@kumc.edu
-
Enrolling Soon
Maryland
Johns Hopkins University, Baltimore, MD 21205
Contact
Britany Zeglin
Phone: +1 (443) 287-8983
Email: bzeglin1@jhmi.edu
-
Enrolling
Missouri
Washington University School of Medicine, St. Louis, MO 63110
Contact
Tina Hicks
Phone: +1 (314) 747-2707
Email: hickst@wustl.edu
-
Enrolling
New York
Long Island Jewish Medical Center, New Hyde Park, NY 11042
Contact
Aileen Espinal
Phone: +1 (516) 465-5400
Email: aespinal2@northwell.edu
-
Enrolling
Pennsylvania
University of Pennsylvania, Philadelphia, PA 19104
Contact
Sara Deitrick
Phone: +1 (215) 615-0276
Email: Sara.deitrick@uphs.upenn.edu
-
Enrolling
South Carolina
Medical University of South Carolina, Charleston, SC 29425
Contact
Ashley Warden
Phone: +1 (843) 792-4349
Email: jonesash@musc.edu
-
Enrolling
Texas
University of Texas Southwestern, Dallas, TX 75390
Contact
Ashley Keller
Phone: +1 (214) 648-2817
Email: Ashley.Keller@UTSouthwestern.edu
Related Topics
-
Questions to Ask When Considering a Specific Trial
Clinical trials that test potential drugs and therapies in people with cystic fibrosis are a major part of CF research. They take place at Cystic Fibrosis Foundation-accredited care centers all over the United States and enroll people with CF of all ages.
-
Patient Safety Is a Priority
Nothing is more important than patient safety in developing new treatments for cystic fibrosis. The U.S. government requires that all clinical trials are supervised for safety, and the Cystic Fibrosis Foundation adds additional measures to protect study volunteers.
-
Trikafta™
The following is a collection of information and news about Trikafta™, the triple-combination modulator therapy that was approved by the U.S. Food and Drug Administration on Oct. 21, 2019.
